HBV mutation literature information.


  Assessment of selective real-time PCR for quantitation of lamivudine and adefovir hepatitis B virus-resistant strains and comparison with direct sequencing and line probe assays.
 PMID: 19041345       2009       Journal of virological methods
Abstract: A selective real-time PCR (sPCR) assay has been developed to detect the rtM204V/I and rtN236T mutations of hepatitis B virus (HBV) associated with resistance to lamivudine and adefovir.


  Complex dynamics of hepatitis B virus resistance to adefovir.
 PMID: 19065672       2009       Hepatology (Baltimore, Md.)
Abstract: UNLABELLED: In patients with hepatitis B e antigen-negative chronic hepatitis B, adefovir dipivoxil administration selects variants bearing reverse transcriptase rtN236T and/or rtA181V/T substitutions in 29% of cases after 5 years.


  Susceptibility of hepatitis B virus to lamivudine restored by resistance to adefovir.
 PMID: 19152408       2009       Journal of medical virology
Abstract: In both patients serial monotherapy caused the replacement in all HBV clones of wild-type virus by classical lamivudine resistant mutants (L180M and M204V/I), which were replaced subsequently by adefovir resistant mutants (A181V and N236T).


  Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients.
 PMID: 19301976       2009       The Journal of infectious diseases
Abstract: UDPS detected drug-resistance mutations that were not detected by PCR in 10 samples from 5 NRTI-treated patients, including the lamivudine-resistance mutation V173L (in 5 samples), the entecavir-resistance mutations T184S (in 2 samples) and S202G (in 1 sample), the adefovir-resistance mutation N236T (in 1 sample), and the lamivudine and adefovir-resistance mutations V173L, L180M, A181T, and M204V (in 1 sample).
Method: Established NRTI-resistance mutations included the following RT mutations: rtL80V/I, rtI169T,  PMID: 19302908       2009       Clinical therapeutics
Abstract: At week 86 during ADV therapy, the rtN236T ADV-resistance mutation was detected in 58.8% (20/34) of clones.


  [A study on the treatment of chronic hepatitis B with YMDD mutation].
 PMID: 19335977       2009       Zhonghua gan zang bing za zhi
Abstract: Two patients had rtN236T mutation in group A, and one patient had rtN236T mutation and another one had rtA181V mutation in group B.


  Alkoxyalkyl esters of 9-(s)-(3-hydroxy-2-phosphonomethoxypropyl) adenine are potent and selective inhibitors of hepatitis B virus (HBV) replication in vitro and in HBV transgenic mice in vivo.
 PMID: 19398648       2009       Antimicrobial agents and chemotherapy
Abstract: HDP-(S)-HPMPA retained full activity against HBV mutants resistant to lamivudine (L180M, M204V), but cross-resistance to a mutant resistant to adefovir (N236T) was detected.


  Adefovir dipivoxil resistance patterns in patients with lamivudine-resistant chronic hepatitis B.
 PMID: 19578241       2009       Antiviral therapy
Abstract: ADV resistance mutations (rtA181V/T and rtN236T) were detected alone or in combination for 11/14 patients, whereas novel substitutions were present in 3 patients.
Abstract: CONCLUSIONS: Although most patients showed virological breakthrough because of the well known rtA181V/T and rtN236T substitutions, more complex patterns were also found.


  Prevalence, viral replication efficiency and antiviral drug susceptibility of rtQ215 polymerase mutations within the hepatitis B virus genome.
 PMID: 19586679       2009       Journal of hepatology
Abstract: Replication-competent HBV constructs containing the naturally occurring rtQ215H, rtQ215P and rtQ215S mutations were generated, and compared to wild-type, LAM- (rtM204I, rtL180M/rtM204V) and ADV-resistant (rtN236T) clones.


  Hepatitis B virus wild-type and rtN236T populations show similar early HBV DNA decline in adefovir refractory patients on a tenofovir-based regimen.
 PMID: 19651117       2009       Clinica chimica acta; international journal of clinical chemistry
Abstract: CONCLUSIONS: The PCR-LDR assay can sensitively and specifically detect the rtA181V/T and rtN236T mutations, and may be used for monitoring ADV resistance in patients infected with HBV.
Abstract: We developed a sensitive and specific method for detecting the rtA181V/T and rtN236T mutations associated with ADV resistance in chronic hepatitis B patients, based on a ligase detection reaction (LDR).



Browser Board

 Co-occurred Entities




   Filtrator